Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALTO-102
- Development stage
- Unknown
- Lead developer
- Alto Neuroscience
- Administration
- Oral
01
Overview
**ALTO-102** was an investigational proprietary combination medicine developed by Alto Neuroscience to modulate the cyclic adenosine monophosphate signaling pathway, a neurobiological pathway implicated in cognition, memory, and mood. It was evaluated in a randomized, placebo-controlled, four-way crossover Phase 1 human brain-mechanism study in 41 healthy adults using low doses of its undisclosed component drugs. ALTO-102 did not demonstrate pharmacodynamic effects on the behavioral, event-related potential, or subjective-response measures evaluated, and Alto did not advance it alongside the more active ALTO-103 and ALTO-104 combinations.
Beyond the preview
Go deeper on ALTO-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALTO-102.